BIIB RSI Chart
Last 7 days
-9.1%
Last 30 days
-11.7%
Last 90 days
-3.9%
Trailing 12 Months
-23.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 10.1B | 10.0B | 10.0B | 9.8B |
2022 | 10.8B | 10.6B | 10.4B | 10.2B |
2021 | 12.6B | 11.7B | 11.1B | 11.0B |
2020 | 14.4B | 14.5B | 14.3B | 13.4B |
2019 | 13.8B | 14.1B | 14.2B | 14.4B |
2018 | 12.6B | 12.9B | 13.2B | 13.5B |
2017 | 11.5B | 11.7B | 11.8B | 12.3B |
2016 | 10.9B | 11.2B | 11.4B | 11.4B |
2015 | 10.1B | 10.3B | 10.6B | 10.8B |
2014 | 7.6B | 8.3B | 9.0B | 9.7B |
2013 | 5.6B | 5.9B | 6.4B | 6.9B |
2012 | 5.1B | 5.3B | 5.4B | 5.5B |
2011 | 4.8B | 4.8B | 4.9B | 5.0B |
2010 | 4.4B | 4.6B | 4.6B | 4.7B |
2009 | 4.2B | 4.3B | 4.3B | 4.4B |
2008 | 0 | 3.5B | 3.8B | 4.1B |
2007 | 0 | 0 | 0 | 3.2B |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 22, 2024 | singhal priya | sold | -57,962 | 221 | -262 | head of development |
Feb 16, 2024 | izzar rachid | acquired | - | - | 2,017 | head of global product strat. |
Feb 16, 2024 | kramer robin | sold (taxes) | -86,755 | 219 | -396 | chief accounting officer |
Feb 16, 2024 | gregory ginger | sold (taxes) | -495,997 | 219 | -2,264 | evp, human resources |
Feb 16, 2024 | singhal priya | sold (taxes) | -102,529 | 219 | -468 | head of development |
Feb 16, 2024 | mcdonnell michael r | acquired | - | - | 6,720 | evp, chief financial officer |
Feb 16, 2024 | alexander susan h | sold (taxes) | -533,898 | 219 | -2,437 | evp chief legal officer |
Feb 16, 2024 | izzar rachid | sold (taxes) | -208,564 | 219 | -952 | head of global product strat. |
Feb 16, 2024 | murphy nicole | sold (taxes) | -133,639 | 219 | -610 | head of pharm ops and tech |
Feb 16, 2024 | singhal priya | acquired | - | - | 1,208 | head of development |
Which funds bought or sold BIIB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 14, 2024 | Leo Wealth, LLC | new | - | 2,264,860 | 2,264,860 | 0.23% |
Mar 12, 2024 | ROVIN CAPITAL /UT/ /ADV | added | 30.34 | 127,000 | 534,000 | 0.24% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 18.2 | 595,596,000 | 3,728,180,000 | 0.08% |
Mar 11, 2024 | Wahed Invest LLC | added | 6.46 | 41,756 | 622,342 | 0.17% |
Mar 08, 2024 | TRUST CO OF VERMONT | reduced | -3.26 | -15,158 | 567,741 | 0.04% |
Mar 07, 2024 | Brown Shipley& Co Ltd | reduced | -69.81 | -130,899 | 57,188 | 0.03% |
Mar 06, 2024 | SageView Advisory Group, LLC | added | 8.19 | 9,061 | 234,973 | 0.01% |
Mar 05, 2024 | Fisher Asset Management, LLC | reduced | -43.96 | -12,743,600 | 16,504,000 | 0.01% |
Mar 05, 2024 | GREENWOOD CAPITAL ASSOCIATES LLC | added | 100 | 5,004,540 | 9,908,300 | 0.64% |
Mar 04, 2024 | Fortis Group Advisors, LLC | added | 100 | 3,909 | 7,764 | -% |
Unveiling Biogen Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Biogen Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 381.0B | 93.0B | 10.84 | 4.47 | ||||
MRK | 307.8B | 60.1B | 843.2 | 5.12 | ||||
PFE | 157.8B | 46.5B | -113.63 | 3.39 | ||||
AMGN | 144.1B | 28.2B | 21.45 | 5.11 | ||||
GILD | 91.8B | 27.1B | 16.21 | 3.39 | ||||
TEVA | 15.0B | 15.8B | -26.11 | 0.95 | ||||
MID-CAP | ||||||||
ALKS | 4.8B | 1.7B | 13.5 | 2.89 | ||||
PRGO | 4.1B | 4.7B | -324.06 | 0.88 | ||||
BHC | 3.4B | 8.8B | -5.68 | 0.38 | ||||
AMPH | 2.1B | 644.4M | 15.05 | 3.21 | ||||
SMALL-CAP | ||||||||
TLRY | 1.3B | 700.5M | -0.9 | 1.83 | ||||
TXMD | 25.4M | 70.0M | 0.37 | 0.34 | ||||
ACRX | 19.9M | - | -1.08 | 0.22 | ||||
ACOR | 15.4M | 111.1M | -0.97 | 0.14 | ||||
AGRX | 1.4M | 20.0M | -0.1 | 0.07 |
Biogen Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -5.7% | 2,386 | 2,530 | 2,456 | 2,463 | 2,544 | 2,509 | 2,589 | 2,532 | 2,734 | 2,779 | 2,775 | 2,694 | 2,853 | 3,376 | 3,682 | 3,534 | 3,671 | 3,600 | 3,617 | 3,490 | 3,526 |
Costs and Expenses | -21.6% | 2,095 | 2,672 | 1,748 | 2,025 | 1,940 | 1,137 | 1,320 | 2,184 | 2,582 | 2,488 | 2,193 | 1,720 | 2,686 | 2,290 | 1,707 | 1,714 | 1,894 | 1,794 | 1,661 | 1,987 | 2,083 |
S&GA Expenses | -22.8% | 609 | 788 | 548 | 605 | 633 | 563 | 573 | 635 | 788 | 654 | 637 | 595 | 806 | 573 | 555 | 570 | 665 | 555 | 588 | 568 | 591 |
EBITDA Margin | -10.5% | 0.21* | 0.23* | 0.38* | 0.44* | 0.43* | 0.40* | 0.29* | 0.22* | 0.23* | 0.21* | 0.26* | 0.36* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 12.1% | 72.00 | 64.00 | 49.00 | 63.00 | 55.00 | 60.00 | 66.00 | 66.00 | 66.00 | 66.00 | 56.00 | 65.00 | 56.00 | 56.00 | 66.00 | 44.00 | 46.00 | 46.00 | 48.00 | 48.00 | 49.00 |
Income Taxes | 158.6% | 43.00 | -72.90 | 115 | 51.00 | 54.00 | 236 | 217 | 126 | 443 | -25.90 | -409 | 44.00 | 13.00 | 241 | 446 | 292 | 276 | 211 | 248 | 423 | 470 |
Earnings Before Taxes | 306.5% | 292 | -141 | 708 | 438 | 604 | 1,371 | 1,270 | 347 | 405 | 291 | 582 | 467 | 353 | 958 | 2,038 | 1,699 | 1,728 | 1,779 | 1,759 | 1,860 | 1,415 |
EBT Margin | -18.1% | 0.13* | 0.16* | 0.31* | 0.36* | 0.35* | 0.33* | 0.22* | 0.15* | 0.16* | 0.15* | 0.20* | 0.30* | - | - | - | - | - | - | - | - | - |
Net Income | 466.7% | 250 | -68.10 | 592 | 388 | 550 | 1,135 | 1,058 | 304 | 368 | 329 | 449 | 410 | 358 | 702 | 1,542 | 1,399 | 1,440 | 1,546 | 1,494 | 1,409 | 947 |
Net Income Margin | -19.3% | 0.12* | 0.15* | 0.27* | 0.31* | 0.30* | 0.28* | 0.19* | 0.13* | 0.14* | 0.14* | 0.16* | 0.24* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -110.2% | -52.70 | 518 | 416 | 389 | -261 | 602 | 700 | 104 | 787 | 763 | 1,155 | 676 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -4.8% | 26,845 | 28,193 | 25,157 | 24,598 | 24,554 | 24,854 | 25,081 | 23,614 | 23,877 | 23,807 | 24,470 | 23,855 | 24,619 | 24,934 | 25,512 | 26,119 | 27,234 | 27,484 | 26,288 | 26,446 | 25,289 |
Current Assets | -18.9% | 6,859 | 8,454 | 10,432 | 9,763 | 9,791 | 9,766 | 9,741 | 7,916 | 7,857 | 7,162 | 7,184 | 6,720 | 6,887 | 7,843 | 8,494 | 8,007 | 8,382 | 8,448 | 7,910 | 8,943 | 7,641 |
Cash Equivalents | -54.1% | 1,050 | 2,288 | 2,618 | 2,898 | 3,419 | 3,676 | 2,647 | 1,749 | 2,261 | 1,542 | 1,742 | 1,218 | 1,331 | 2,225 | 2,385 | 2,591 | 2,914 | 2,344 | 1,723 | 2,243 | 1,225 |
Inventory | -15.3% | 2,527 | 2,982 | 1,334 | 1,281 | 1,344 | 1,375 | 1,294 | 1,215 | 1,352 | 1,348 | 1,255 | 1,172 | 1,069 | 1,028 | 953 | 859 | 804 | 752 | 777 | 770 | 930 |
Net PPE | 0.2% | 3,310 | 3,302 | 3,307 | 3,301 | 3,299 | 3,266 | 3,355 | 3,373 | 3,416 | 3,411 | 3,442 | 3,438 | 3,412 | 3,360 | 3,331 | 3,282 | 3,247 | 3,138 | 3,078 | 3,014 | 3,601 |
Goodwill | 1238.9% | 6,219 | 465 | 5,754 | 5,752 | 5,749 | 5,741 | 5,750 | 5,758 | 5,761 | 5,761 | 5,764 | 5,763 | 5,762 | 5,756 | 5,751 | 5,752 | 5,758 | 5,746 | 5,749 | 5,640 | 5,706 |
Liabilities | -12.2% | 12,045 | 13,714 | 10,696 | 10,811 | 11,166 | 12,087 | 13,218 | 12,394 | 12,918 | 12,925 | 13,256 | 13,192 | 13,933 | 14,190 | 14,223 | 13,582 | 13,895 | 13,492 | 13,339 | 12,624 | 12,257 |
Current Liabilities | -31.6% | 3,434 | 5,022 | 3,187 | 3,015 | 3,273 | 3,926 | 5,018 | 3,947 | 4,298 | 4,212 | 3,347 | 3,166 | 3,742 | 3,804 | 3,447 | 4,639 | 4,864 | 4,432 | 3,211 | 3,149 | 3,295 |
Long Term Debt | -100.0% | - | 6,786 | 6,285 | 6,283 | 6,281 | 6,279 | 6,277 | 6,276 | 6,274 | 6,272 | 7,269 | 7,267 | 7,426 | 7,425 | 7,424 | 4,460 | 4,459 | 4,458 | 5,949 | 5,943 | 5,937 |
Shareholder's Equity | 2.2% | 14,799 | 14,484 | 14,461 | 13,787 | 13,398 | 12,767 | 11,863 | 11,221 | 10,960 | 10,882 | 11,215 | 10,663 | 10,686 | 10,745 | 11,289 | 12,537 | 13,339 | 13,992 | 12,949 | 13,822 | 13,032 |
Retained Earnings | 1.4% | 17,628 | 17,378 | 17,446 | 16,854 | 16,467 | 15,916 | 14,960 | 14,216 | 13,912 | 13,544 | 13,901 | 13,834 | 13,976 | 13,961 | 14,467 | 15,673 | 16,455 | 17,065 | 16,183 | 17,027 | 16,257 |
Additional Paid-In Capital | 24.9% | 303 | 242 | 171 | 91.00 | 73.00 | - | - | 119 | 68.00 | - | - | - | - | - | - | 0.00 | - | - | - | - | - |
Shares Outstanding | 0.1% | 145 | 145 | 145 | 144 | 144 | 144 | 147 | 147 | 147 | 150 | 151 | 152 | - | - | - | - | - | - | - | - | - |
Minority Interest | 100.0% | - | -4.10 | -6.40 | -9.60 | -9.50 | -8.70 | -9.10 | -21.60 | 64.00 | 452 | 463 | -19.00 | -14.20 | -14.00 | -19.50 | -10.00 | -4.10 | -4.10 | -4.10 | -7.90 | -8.00 |
Float | - | - | - | 41,191 | - | - | - | 29,398 | - | - | - | 51,265 | - | - | - | 42,103 | - | - | - | 43,010 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -97.9% | 13.00 | 592 | 487 | 455 | -175 | 661 | 737 | 162 | 838 | 805 | 1,227 | 769 | -367 | 1,181 | 1,949 | 1,467 | 1,960 | 1,695 | 1,964 | 1,460 | 1,895 |
Share Based Compensation | 395.1% | 191 | -64.80 | -74.10 | 76.00 | 189 | -65.70 | -58.00 | 68.00 | 170 | -57.60 | -55.80 | 70.00 | 132 | -35.40 | -49.50 | 68.00 | 139 | -47.80 | -55.00 | 46.00 | 35.00 |
Cashflow From Investing | 62.6% | -652 | -1,742 | -753 | -953 | -141 | 1,672 | 694 | -648 | -112 | -233 | -152 | -64.70 | -166 | -52.40 | -832 | 443 | 708 | -365 | -110 | 239 | -1,625 |
Cashflow From Financing | -176.1% | -646 | 849 | -9.80 | -43.40 | -7.40 | -1,251 | -471 | -16.50 | 10.00 | -746 | -564 | -785 | -401 | -1,312 | -1,313 | -2,245 | -2,116 | -689 | -2,375 | -679 | -1,437 |
Buy Backs | - | - | - | - | - | - | 250 | 500 | - | - | 750 | 450 | 600 | 400 | 1,250 | 2,809 | 2,220 | 2,093 | 718 | 2,402 | 656 | 1,353 |
Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues | $ 9,835.6 | $ 10,173.4 | $ 10,981.7 |
Cost and expense: | |||
Cost of sales, excluding amortization and impairment of acquired intangible assets | 2,533.4 | 2,278.3 | 2,109.7 |
Research and development | 2,462.0 | 2,231.1 | 2,501.2 |
Selling, general and administrative | 2,549.7 | 2,403.6 | 2,674.3 |
Amortization and impairment of acquired intangible assets | 240.6 | 365.9 | 881.3 |
Collaboration profit sharing/(loss reimbursement) | 218.8 | (7.4) | 7.2 |
(Gain) loss on fair value remeasurement of contingent consideration | 0.0 | (209.1) | (50.7) |
Acquired in-process research and development | 0.0 | 0.0 | 18.0 |
Restructuring charges | 218.8 | 131.1 | 0.0 |
Gain on sale of building | 0.0 | (503.7) | 0.0 |
Other (income) expense, net | 315.5 | (108.2) | 1,095.5 |
Total cost and expense | 8,538.8 | 6,581.6 | 9,236.5 |
Income before income tax (benefit) expense and equity in loss of investee, net of tax | 1,296.8 | 3,591.8 | 1,745.2 |
Income tax (benefit) expense | 135.3 | 632.8 | 52.5 |
Equity in (income) loss of investee, net of tax | 0.0 | (2.6) | (34.9) |
Net income | 1,161.5 | 2,961.6 | 1,727.6 |
Net income (loss) attributable to noncontrolling interests, net of tax | 0.4 | (85.3) | 171.5 |
Net income attributable to Biogen Inc. | $ 1,161.1 | $ 3,046.9 | $ 1,556.1 |
Net income per share: | |||
Basic earnings per share attributable to Biogen Inc. (in dollars per share) | $ 8.02 | $ 20.96 | $ 10.44 |
Diluted earnings per share attributable to Biogen Inc. (in dollars per share) | $ 7.97 | $ 20.87 | $ 10.40 |
Weighted-average shares used in calculating: | |||
Weighted average number of common shares outstanding (in shares) | 144,700 | 145,300 | 149,100 |
Diluted earnings per share attributable to Biogen Inc. (in shares) | 145,600 | 146,000 | 149,600 |
Product revenue, net | |||
Revenues | $ 7,246.7 | $ 7,987.8 | $ 8,846.9 |
Revenue from anti-CD20 therapeutic programs | |||
Revenues | 1,689.6 | 1,700.5 | 1,658.5 |
Contract manufacturing, royalty and other revenue | |||
Revenues | $ 899.3 | $ 485.1 | $ 476.3 |
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,049.9 | $ 3,419.3 |
Marketable securities | 0.0 | 1,473.5 |
Accounts receivable, net of allowance for doubtful accounts of $2.4 and $2.3, respectively | 1,664.1 | 1,705.0 |
Due from anti-CD20 therapeutic programs | 435.9 | 431.4 |
Inventory | 2,527.4 | 1,344.4 |
Other current assets | 1,182.0 | 1,417.6 |
Total current assets | 6,859.3 | 9,791.2 |
Marketable securities | 0.0 | 705.7 |
Property, plant and equipment, net | 3,309.7 | 3,298.6 |
Operating lease assets | 420.0 | 403.9 |
Intangible assets, net | 8,363.0 | 1,850.1 |
Goodwill | 6,219.2 | 5,749.0 |
Deferred tax asset | 928.6 | 1,226.4 |
Investments and other assets | 745.0 | 1,529.2 |
Total assets | 26,844.8 | 24,554.1 |
Current liabilities: | ||
Current portion of term loan | 150.0 | 0.0 |
Taxes payable | 257.4 | 259.9 |
Accounts payable | 403.3 | 491.5 |
Accrued expense and other | 2,623.6 | 2,521.4 |
Total current liabilities | 3,434.3 | 3,272.8 |
Notes payable and term loan | 6,788.2 | 6,281.0 |
Deferred tax liability | 641.8 | 334.7 |
Long-term operating lease liabilities | 400.0 | 333.0 |
Other long-term liabilities | 781.1 | 944.2 |
Total liabilities | 12,045.4 | 11,165.7 |
Commitments, contingencies and guarantees (Notes 22 and 23) | ||
Biogen Inc. shareholders’ equity | ||
Preferred stock, par value $0.001 per share | 0.0 | 0.0 |
Common stock, par value $0.0005 per share | 0.1 | 0.1 |
Additional paid-in capital | 302.5 | 73.3 |
Accumulated other comprehensive income (loss) | (153.7) | (164.9) |
Retained earnings | 17,627.6 | 16,466.5 |
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively | (2,977.1) | (2,977.1) |
Total Biogen Inc. shareholders’ equity | 14,799.4 | 13,397.9 |
Noncontrolling interests | 0.0 | (9.5) |
Total equity | 14,799.4 | 13,388.4 |
Total liabilities and equity | $ 26,844.8 | $ 24,554.1 |